Real-world experience of immune checkpoint inhibitors in MSI-H/dMMR metastatic colorectal cancer in a tertiary cancer center in Saudi Arabia

被引：0
|
作者：
Ajina, R. [1 ]
Alhareeri, A. [1 ]
Philip, W. [1 ]
Alsekait, N. [2 ]
Alarifi, N. [2 ]
Alismail, H. [1 ]
Alshieban, S. [3 ]
Almuzzaini, B. [4 ]
Alshammari, K. [5 ]
机构：
[1] King Saud bin Abdulaziz Univ Hlth Sci, KAIMRC, Minist Natl Guard Hlth Affairs, Riyadh, Saudi Arabia
[2] King Saud Bin Abdulaziz Univ Hlth Sci, Riyadh, Saudi Arabia
[3] King Saud bin Abdulaziz Univ Hlth Sci, King Abdulaziz Med City, KAIMRC, Minist Natl Guard Hlth Affairs, Riyadh, Saudi Arabia
[4] KSAU HS, King Abdullah Int Med Res Ctr, Minist Natl Guard Hlth Affairs, Riyadh, Saudi Arabia
[5] Minist Natl Guard Hlth Affairs, Riyadh, Saudi Arabia
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.04.344
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-288
引用
收藏
页码：S117 / S117
页数：1
相关论文
共 50 条
  • [31] Immune checkpoint inhibitors in digestive tumors with mismatch repair deficiency or microsatellite instability (dMMR/MSI-H): Effectiveness, safety, and prognostic factors in real-world practice.
    Lago, Nieves Martinez
    Castineira, Antia Cousillas
    Jara-Martin, Pablo
    Reboredo, Margarita
    Villarroel, Paula Gonzalez
    Covela, Marta
    Lopez, Carlos Lopez
    Suarez, Begona Grana
    Martin, Elena Gallardo
    Gomez, Juan De la Camara
    Garcia-Lorenzo, Carme
    Maseda, Alberto Carral
    Martelo, Martin Perez
    Montes, Ana Fernandez Fernandez
    Rivera, Fernando
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 202 - 202
  • [32] The controversial abscopal effect: A single-center experience about the combination of stereotactic radiotherapy with pembrolizumab in patients with metastatic dMMR/MSI-H colorectal cancer
    Gandini, Annalice
    Martelli, Valentino
    Belgioia, Liliana
    Puglisi, Silvia
    Cremante, Malvina
    Murianni, Veronica
    Damassi, Alessandra
    Ricciotti, Ilaria
    Pirrone, Chiara
    Catalano, Fabio
    Grassi, Massimiliano
    Pessino, Anna Maria
    Pastorino, Alessandro
    Sciallero, Stefania
    Puccini, Alberto
    Sobrero, Alberto F.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [33] Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms
    Ibrahim Halil Sahin
    Mehmet Akce
    Olatunji Alese
    Walid Shaib
    Gregory B. Lesinski
    Bassel El-Rayes
    Christina Wu
    British Journal of Cancer, 2019, 121 : 809 - 818
  • [34] Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms
    Sahin, Ibrahim Halil
    Akce, Mehmet
    Alese, Olatunji
    Shaib, Walid
    Lesinski, Gregory B.
    El-Rayes, Bassel
    Wu, Christina
    BRITISH JOURNAL OF CANCER, 2019, 121 (10) : 809 - 818
  • [35] Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status
    Loupakis, Fotios
    Maddalena, Giulia
    Depetris, Ilaria
    Murgioni, Sabina
    Bergamo, Francesca
    Dei Tos, Angelo Paolo
    Rugge, Massimo
    Munari, Giada
    Nguyen, Andrew
    Szeto, Christopher
    Zagonel, Vittorina
    Lonardi, Sara
    Fassan, Matteo
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01)
  • [36] Effect of RAS mutations and related immune characteristics on the prognosis of patients with MSI-H/dMMR colorectal cancer
    Jiang, Yupeng
    Liu, Yuyao
    Huang, Hong
    Zhao, Tiantian
    Zhao, Zengyi
    Gao, Yawen
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2025, 74 (03)
  • [37] Real-life efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient (dMMR/ MSI-H) biliary tract cancer (BTC)
    le Brun, I. Campo
    Grapinet, E.
    Hollebecque, A.
    Aurillac, V.
    Parent, P.
    Girot, P.
    Gendreau, M.
    Rafert, S.
    Javed, S.
    Touchefeu, Y.
    Roth, G.
    Muller, M.
    Lequoy, M.
    Boileve, A.
    Decraecker, M.
    ANNALS OF ONCOLOGY, 2024, 35 : S125 - S125
  • [38] Long-term survivals of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy in dMMR/MSI-H colorectal and gastric cancers
    Wang, Zhenghang
    Cheng, Siyuan
    Yao, Yanhong
    Liu, Shengde
    Liu, Zimin
    Liu, Ning
    Jin, Yongdong
    Zhang, Yinjie
    Yin, Fei
    Han, Guangjie
    Zhang, Jingdong
    Wang, Qiwei
    Yan, Dong
    Wang, Li
    Lu, Hongxia
    Deng, Ting
    Ji, Zhi
    Gao, Hui
    Fang, Weijia
    Zhang, Hangyu
    Chen, Zhiyu
    Zou, Jianling
    Tang, Yong
    Xu, Chunlei
    Li, Jiayi
    Qu, Huajun
    Bao, Liying
    Cao, Baoshan
    Wang, Xicheng
    Xu, Ting
    Sun, Yu
    Shen, Lin
    Peng, Zhi
    Li, Jian
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (09)
  • [39] Real world data of safety of immune-checkpoint inhibitors in patient with cancer at tertiary care hospital in Saudi Arabia.
    Alanazi, Ahmed
    Alzaharani, Iman
    Bashir, Mohammed Salman
    AlNajjar, Fouad H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] Immunotherapy outcomes in dMMR/MSI-H and/or TMB-H metastatic colorectal cancer (CRC) with peritoneal metastases (PM).
    Mosalem, Osama M.
    Elhariri, Ahmed
    Wiest, Nathaniel Edward
    Kamatham, Saivaishnavi
    Abdel-Razeq, Nayef Hikmat
    Jones, Jeremy Clifton
    Sonbol, Mohamad B.
    Jin, Zhaohui
    Babiker, Hani M.
    Bekaii-Saab, Tanios S.
    Majeed, Umair
    Starr, Jason S.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 163 - 163
12345